Siemens Healthineers AG (SMMNY) Discusses Q2 Pre-Close Outlook With Focus on Foreign Exchange and Tariff Headwinds Prepared Remarks Transcript

Siemens Healthineers expects a translational revenue headwind of greater than ~5% in Q2 FY2026 (Q1 translational headwind was ~5%). Management flagged two major adjusted-EBIT headwinds for FY2026: foreign exchange and tariffs, and assumed an incremental FX-related EPS headwind of ~EUR 0.15. The remarks are a pre-close outlook ahead of the March 31 quarter end and imply downside pressure on reported revenue and EPS versus prior models.

Analysis

The combination of translational FX pressure and tariff-driven cost steps will act as a double whammy on margin conversion this fiscal year, not just on headline EPS but on free cash flow timing. Expect management choices to shift toward protecting margins — slower buybacks, tighter discretionary OPEX, and faster service/upgrade pricing — which will mute near-term cyclical leverage even if core demand for installable capital remains intact.

Competitive effects will be uneven: companies with larger installed-base recurring revenue and localized manufacturing (aftermarket-heavy or US/EU localized production) will suffer less than those with higher exposure to cross-border equipment sales and global OEM supply chains. Second-order winners include independent service providers and local component suppliers who can arbitrage tariffed finished goods by offering retrofit or maintenance alternatives; losers include China-dependent sub-suppliers whose cost inflation will feed back into longer lead times and project pushouts.

Key catalysts to watch are FX realized rates vs hedged rates, tariff enforcement/waiver developments, and any explicit margin remediation steps announced at the next results cycle. These can swing sentiment quickly: a modest FX stabilization or tariff mitigation could restore 50-70% of near-term EPS downside, while renewed USD weakness or expanded tariff lists would push revisions deeper over 3–9 months. Position sizing should assume asymmetric event risk around quarterly reporting and policy noise over the next 2–6 months.

Key Decisions for Investors

• Pair trade (6–12 months): Short SMMNY vs Long DHR — size to be beta-neutral. Rationale: hedge idiosyncratic FX/tariff sensitivity while capturing relative operational resilience in DHR. Target 10–20% relative outperformance; stop-loss at 15% adverse divergence.
• Protective/options hedge on SMMNY (3–9 months): Buy a put spread to cap downside (pay ~3–6% of notional for protection down ~20–30%) and finance with a covered-call or sell a higher-strike call with the same tenor. Use this before the next quarterly release to limit event risk while retaining upside.
• Overweight recurring-revenue peers (3–12 months): Add DHR and ABT — these names should see less translational squeeze and have better domestic manufacturing footprints. Expect 8–15% relative upside if FX/tariff headwinds persist for the sector.
• FX hedge (1–6 months): Buy EURUSD call options or enter forward EUR buys sized to offset a portion of euro-reported earnings exposure (~20–40% of estimated translational risk). Cost is limited to premium but can recoup a material part of translational EPS swing if EUR rebounds.